Table 1.
Summary of efficacy data from randomized, controlled phase III trials of bevacizumab in advanced ovarian cancer
| Study (n) | Regimen |
ORR (CR + PR), % |
Median PFS, months |
Median OS, months |
|---|---|---|---|---|
| [p value] | [HR; p value] | [HR; p value] | ||
| GOG-0218 [21] |
CP + placebo vs. CP + Bev vs. CP + Bev → Bev maintenance |
– |
10.3 vs. 11.2 vs. 14.1 |
39.3 vs. 38.7 vs. 39.7 |
| (n = 1,873) |
[0.908; 0.16]a |
[1.036; 0.76]a |
||
| [0.717; < 0.001]b |
[0.915; 0.45]b |
|||
| ICON7 [22,23] |
CP vs. CP + Bev → Bev maintenance |
48 vs. 67 |
17.4 vs. 19.8 |
Restricted mean survival time, months |
| (n = 1,528) |
[< 0.001] |
[0.87; 0.04] |
44.6 vs. 44.5 |
|
| OCEANS [24,25] |
CG + placebo vs. CG + Bev |
57.4 vs. 78.5 |
8.4 vs. 12.4 |
33.7c vs. 33.4c |
| (n = 484) |
[< 0.0001] |
[0.484; < 0.0001] |
[0.960; 0.736] |
|
| AURELIA [26,27] |
CTx (PLD, P or Top) vs. CTx + Bev |
12.6 vs. 30.9 |
3.4 vs. 6.7 |
13.3 vs. 16.6 |
| (n = 361) | [0.001] | [0.48; < 0.001] | [0.85; 0.174] |
Bev = bevacizumab. C = carboplatin. CR = complete response. CTx = chemotherapy. G = gemcitabine. HR = hazard ratio. ORR = overall response rate. OS = overall survival. P = paclitaxel. PFS = progression-free survival. PLD = pegylated liposomal doxorubicin. PR = partial response. Top = topotecan.
aCP + Bev vs. CP + placebo.
bCP + Bev → Bev vs. CP + placebo.
cInterim data.